Methods for inhibiting cell proliferation in EGFR-driven cancers

A cancer, subject technology, applied in chemical instruments and methods, botanical equipment and methods, pharmaceutical formulations, etc., to solve problems such as limited resistance to gefitinib and erlotinib

Active Publication Date: 2013-06-12
TAKEDA PHARMA CO LTD
View PDF9 Cites 62 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the clinical efficacy of gefitinib and erlotinib is ultimately limited by the development of resistance, such as mutations in the gatekeeper residue (T790M) of the EGFR kinase domain, which occurs in 50% of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for inhibiting cell proliferation in EGFR-driven cancers
  • Methods for inhibiting cell proliferation in EGFR-driven cancers
  • Methods for inhibiting cell proliferation in EGFR-driven cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1. Kinase Analysis

[0151] In vitro kinase panels were analyzed with WT EGFR, L858R, T790M and L858R / T790M. Additional analyzes can be performed on panels further comprising delE746_A750 and delE746_A750 / T790M. Assay conditions consisted of a 10-point curve with a maximum concentration (single) of 3 μM and 10 μM ATP.

[0152]Compounds of formula (I) include potent inhibitors of EGFR mutants in kinase assays. For example, in the H1975 cell line with the L858R and T790M mutations, previously known inhibitors gefitinib, CL-387,785, and HKI-272 had IC50 values ​​ranging from 153 nM to >3.3 μM, whereas many of the formula (I ) compounds exhibited IC50 values ​​ranging from 0.5 to 9 nM. Therefore, compounds of formula (I) may provide essential inhibitors of EGFR-induced cancers.

Embodiment 2

[0153] Example 2. Cellular and in vivo analysis

[0154] NSCLC cell lines as well as engineered Ba / F3 and NIH3T3 cell lines were used to test the activity of compounds of formula (I) against the following three conventional forms of EGFR: native EGFR (naturally occurring form), EGFR with activating mutations (delE746_A750 [Del] or L858R; this form is sensitive to first-generation EGFR inhibitors) and EGFR with an activating mutation and a T790M resistance mutation (L858R / T790M or Del / T790M; addition of the T790M mutation makes this form sensitive to second-generation EGFR resistance to first-generation EGFR inhibitors). The effect of test compounds on EGFR signaling is assessed by measuring the level of phosphorylated EGFR, the effect on proliferation in vitro is measured by growth and survival assays, and the effect on tumor growth in vivo is measured following daily oral dosing in mice.

[0155] The test compounds of most interest were essentially inactive against native EG...

Embodiment 3

[0159] Example 3. Cell Inhibition Assay

[0160] Lung cancer cell lines were analyzed by measuring the phosphorylation and expression levels of various proteins. For lung cancer cell lines with different EGFR mutant strains, immunoblot analysis of phosphorylation and expression levels of EGFR and other proteins in lung cancer cells was performed. H358 expresses WT EGFR, HCC827 has the delE746_A750 mutation, H820 has the delE746_E749 / T790M mutation, and H1975 has the L858R / T790M mutation.

[0161] Immunoblot analysis was performed on a variety of compounds, including erlotinib, gefitinib, BIBW2992, WZ4003 and several compounds of formula (I).

[0162] This immunoblotting shows that the tested compounds of formula (I) potently inhibit cancer cell lines with EGFR mutations. In particular, the compounds were effective against mutations commonly associated with drug resistance, such as T790M and the combination of L858R and T790M.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.

Description

Background of the invention [0001] The present invention relates to pharmaceutical compositions and methods for inhibiting cell proliferation and treating certain cancers. [0002] Specific genetic lesions that drive cancer cell proliferation, such as those that cause activation of certain tyrosine kinases, make some cancers highly sensitive to therapeutics that inhibit the kinases. However, the efficacy of such agents is often limited by the development of mutations in the target kinase domain that confer resistance by reducing inhibitor binding. [0003] For example, the ABL kinase inhibitor imatinib has revolutionized the treatment of patients with chronic myeloid leukemia (CML) whose disease is caused by an activated BCR-ABL fusion oncoprotein. However, over time, the development of mutations in the ABL kinase domain confers resistance in a substantial proportion of patients. The second-generation ABL inhibitors, dasatinib and nilotinib, have shown superior efficacy as t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/54A61K31/505
CPCA61K31/505A61P35/00C07D401/12C07F9/65583C07F9/6561C07F9/6568
Inventor D.C.达尔加诺W.C.莎士比亚朱笑天V.M.里维拉J.J.米雷特
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap